ALSTON & BIRD LLP for NOVO NORDISK INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues related to H.R. 1628, American Health Care Act, Section 221.
Foreign entity interest: To the extent that Novo Nordisk Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, Novo Nordisk Fonden.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
Health Issues HCR
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; cost of diabetes generally; H.R. 309, National Clinical Care Commission Act.
Foreign entity interest: To the extent that Novo Nordisk Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, Novo Nordisk Fonden.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOYCE E GRESKO | — |
| EARL POMEROY | — |
| MARK RAYDER | — |
| COLIN ROSKEY | — |
| REGINA MARIA SHERICK | — |
| ROBERT SIGGINS | — |
| DANIELLE WHITE | — |
| MARILYN K YAGER | — |
Medicare/Medicaid MMM
Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 1953 and S. 830 Treat and Reduce Obesity Act; Medicare diabetes screening generally.
Foreign entity interest: To the extent that Novo Nordisk Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, Novo Nordisk Fonden.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOYCE E GRESKO | — |
| MARK RAYDER | — |
| COLIN ROSKEY | — |
| REGINA MARIA SHERICK | — |
| ROBERT SIGGINS | — |
| DANIELLE WHITE | — |
Budget/Appropriations BUD
Issues related to National Diabetes Prevention Program. FY17 Labor/HHS/Education Appropriations.
Foreign entity interest: To the extent that Novo Nordisk Inc. realizes any benefit from legislative or executive action, so, too, would its parent company, Novo Nordisk Fonden.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARK RAYDER | — |
| REGINA MARIA SHERICK | — |
| ROBERT SIGGINS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.